Form 424B5 Wave Life Sciences Ltd.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
B.Riley Reiterates Buy Rating on WAVE Life Sciences (WVE)
September 25, 2024 6:24 AM EDTB.Riley analyst Madison El-Saadi reiterated a Buy rating and $11.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "In totality, we believe results exceeded our/investor expectations (9/18 initiation) and replicated the preclinical and early clinical datasets indicative of best-in-class exon skipping profile... More
WAVE Life Sciences (WVE) no longer intends to offers ordinary shares
September 24, 2024 5:23 PM EDTWAVE Life Sciences (NASDAQ: WVE) has filed the following prospectus:
This Prospectus Supplement No. 1 supplements and amends the prospectus dated May 4, 2022 (the Prospectus), covering the offering, issuance and sale of up to a maximum aggregate offering amount of $131,974,010 (the Maximum Offering Amount) of our... More



